Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Sumitomo Dainippon Pharma Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Sumitomo Dainippon Pharma Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sumitomo Dainippon Pharma Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Sumitomo Dainippon Pharma Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Sumitomo Dainippon Pharma Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Sumitomo Dainippon Pharma Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Sumitomo Dainippon Pharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Sumitomo Dainippon Pharma Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Sumitomo Dainippon Pharma Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Sumitomo Dainippon Pharma Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sumitomo Dainippon Pharma Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Sumitomo Dainippon Pharma Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Sumitomo Dainippon Pharma Co., Ltd. Snapshot 8
Sumitomo Dainippon Pharma Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Sumitomo Dainippon Pharma Co., Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products Glance 19
Sumitomo Dainippon Pharma Co., Ltd. - Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
Sumitomo Dainippon Pharma Co., Ltd. - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
Sumitomo Dainippon Pharma Co., Ltd. - Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 24
Sumitomo Dainippon Pharma Co., Ltd. - Drug Profiles 25
amrubicin hydrochloride 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
blonanserin 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
droxidopa 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
lurasidone hydrochloride 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ranirestat 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
vatiquinone 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
afacifenacin 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DSP-6952 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
obeticholic acid 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
zonisamide 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
EPI-589 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
WT-2725 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
WT-4869 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DSP-0011 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DSR-6434 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NEP-28 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SM-276001 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SM-295291 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SM-324405 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SM-369926 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Activate Translocator Protein for Anxiety 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Target Ras Signaling Pathway for Cancer 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Apoptosis Inhibitor Of Macrophages 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HLS-001 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecule to Antagonize GCGR for Type 2 Diabetes 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Inhibit CaMKII for Undisclosed Indication 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules to Inhibit mPGES-1 for Inflammation 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Analysis 67
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Target 67
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Route of Administration 70
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Molecule Type 71
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action 72
Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates 75
Sumitomo Dainippon Pharma Co., Ltd. - Dormant Projects 96
Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products 97
Discontinued Pipeline Product Profiles 97
emapunil 97
rafabegron 97
ceftaroline fosamil 98
DSP-0565 98
DSP-3025 98
DSP-7238 98
DSP-9599 98
KGA-3235 98
limaprost 99
rafabegron 99
ranirestat 99
resequinil 99
rimacalib 99
SEP-225425 99
SEP-226332 99
SEP-227162 100
SEP-227900 100
SMP-028 100
SMP-797 100
Sumitomo Dainippon Pharma Co., Ltd. - Company Statement 101
Sumitomo Dainippon Pharma Co., Ltd. - Locations And Subsidiaries 102
Head Office 102
Other Locations & Subsidiaries 102
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 108
Disclaimer 108

List of Tables
Sumitomo Dainippon Pharma Co., Ltd., Key Information 8
Sumitomo Dainippon Pharma Co., Ltd., Key Facts 8
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Indication, 2014 10
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Stage of Development, 2014 13
Sumitomo Dainippon Pharma Co., Ltd. - Monotherapy Products in Pipeline, 2014 14
Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products in Pipeline, 2014 15
Sumitomo Dainippon Pharma Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 16
Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products in Pipeline, 2014 17
Sumitomo Dainippon Pharma Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 18
Sumitomo Dainippon Pharma Co., Ltd. - Pre-Registration, 2014 19
Sumitomo Dainippon Pharma Co., Ltd. - Phase III, 2014 20
Sumitomo Dainippon Pharma Co., Ltd. - Phase II, 2014 21
Sumitomo Dainippon Pharma Co., Ltd. - Phase I, 2014 22
Sumitomo Dainippon Pharma Co., Ltd. - Preclinical, 2014 23
Sumitomo Dainippon Pharma Co., Ltd. - Discovery, 2014 24
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Target, 2014 68
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Route of Administration, 2014 70
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline by Molecule Type, 2014 71
Sumitomo Dainippon Pharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 73
Sumitomo Dainippon Pharma Co., Ltd. - Recent Pipeline Updates, 2014 75
Sumitomo Dainippon Pharma Co., Ltd. - Dormant Developmental Projects,2014 96
Sumitomo Dainippon Pharma Co., Ltd. - Discontinued Pipeline Products, 2014 97
Sumitomo Dainippon Pharma Co., Ltd., Other Locations 102
Sumitomo Dainippon Pharma Co., Ltd., Subsidiaries 105